Outcomes of a multidisciplinary team approach to cardiovascular risk reduction in patients with diabetes mellitus

Therapy

Volumn 2, Issue 4, 2005, Pages 587-595

  Taylor, Angela M ^a   McNamara, Coleen A ^a   Hedelt, Anne ^a   Chaney, Cherie ^a   Perry, Mary Lou ^a   Miller III, Thomas M ^a   Tyler, Karen D ^a   McCall, Anthony L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Diabetes; Dyslipidemia; Multidisciplinary; Outcomes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERTENSION; LIFESTYLE; MALE; MEDICAL SPECIALIST; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION;

EID: 22544459337     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.4.587     Document Type: Article

References (28)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III): JAMA 285 (19), 2486-2497 (2001).
2. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Diabetes in America National Diabetes Data Group (Eds), Washington, DC, USA: National Institutes of Health, NIDDK NIH publication no. 95-1468, 429-448 (1995).
3. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs. women. The Framingham Study. JAMA 260(23), 3456-3460 (1998).
4. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 21(7), 1138-1145 (1998).
5. Engelgau MM, Geiss LS, Saaddine JB et al. The evolving diabetes burden in the United States. Ann. Intern. Med. 140(11), 945-950 (2004).
6. Bonow RO, Gheorghiade M. The diabetes epidemic: a national and global crisis. Am. J. Med. 116(Suppl-10S) (2004).
7. Kramer D, Raji A, Plutzky J. Prediabetes mellitus and its links to atherosclerosis. Curr. Diabetes Rep. 3(1), 11-18 (2003).
8. George PB, Tobin KJ, Corpus RA, Devlin WH, O'Neill WW. Treatment of cardiac risk factors in diabetic patients: how well do we follow the guidelines? Am. Heart J. 142(5), 857-863 (2001).
9. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393-403 (2002).
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131), 837-853 (1998).
11. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br. Med. J. 317(7160), 703-713 (1998).
12. Malmberg K. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Br. Med. J. 314(7093), 1512-1515 (1997).
13. Van Den BG, Wouters P. Weekers F et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345(19), 1359-1367 (2001).
14. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329(14), 977-986 (1993).
15. Riddle MC, Rosenstock J, Gerich J, Insulin G. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care 26(11), 3080-3086 (2003).
16. McFarlane SI, Jacober SJ, Winer N et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 25(4), 718-723 (2002).
17. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291(3), 335-342 (2004).
18. Singer GM, Izhar M, Black HR. Guidelines for hypertension: are quality-assurance measures on target? Hypertension 43(2), 198-202 (2004).
19. Pladevall M, Tuniceli K, Lafata J. Trends in the management of dyslipidemia in patients with diabetes. Presented at the 64th Scientific Sessions of the American Diabetes Association, 4-8 June FL, USA (2005) (Abstract).
20. Cziracy M, Willey V, Bullano M. Assessment of combined lipid goal attainment in 8855 diabetic patients. Presented at the 64th Scientific Sessions of the American Diabetes Association, 4-8 June FL, USA (2005) (Abstract).
21. Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki-Jarvinen H. Insulin therapy induces anti-atherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8(2), 168-77 (1988).
22. Coon P, Zulkowski K. Adherence to American Diabetes Association standards of care by rural healthcare providers. Diabetes Care 25(12), 2224-9 (2002).
23. Putzer G, Roetzheim R, Ramirez AM, Sneed K, Brownlee HJ Jr., Campbell RJ. Compliance with recommendations for lipid management among patients with type 2 diabetes in an academic family practice. J. Am. Board Fam. Prac. 17(2), 101-107 (2004).
24. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348(5), 383-393 (2003).
25. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351(9118), 1755-1762 (1998).
26. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335(14), 1001-1009 (1996).
27. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339(19), 1349-1357 (1998).
28. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374), 2005-2016 (2003).